Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
暂无分享,去创建一个
C. Porta | R. Montironi | Liang Cheng | M. Scarpelli | F. Atzori | M. Milella | F. Calabrò | S. Buti | A. Cimadamore | F. Massari | S. Crabb | U. de Giorgi | R. Iacovelli | M. Santoni | D. Santini | S. Bracarda | F. Piva | F. Morelli | G. Procopio | U. Basso | P. Zucali | G. Cartenì | O. Caffo | M. Rizzo | E. Verzoni | F. Carrozza | A. Mosca | A. Conti | M. Matrana | A. Gelibter | L. Incorvaia | M. G. Vitale | R. Ricotta | N. Battelli | C. Ortega | G. Fornarini | D. Heng | V. Paolucci | G. Sorgentoni | L. Galli | S. Scagliarini | J. Graham | S. Merler | A. Martignetti | P. Sepe | C. Masini | N. Vau | A. López-Beltran | Erin Pierce
[1] T. Powles,et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[2] R. Motzer,et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[3] R. Montironi,et al. Tivozanib for the treatment of renal cell carcinoma , 2018, Expert opinion on pharmacotherapy.
[4] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[5] T. Choueiri,et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update , 2018, European journal of cancer.
[6] R. Nolley,et al. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation , 2017, Cancer biology & therapy.
[7] F. Massari,et al. The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma , 2017 .
[8] S. Buti,et al. Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma? , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Choueiri,et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Powles,et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[11] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[12] P. Kantoff,et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[13] C. Porta,et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma , 2015, British Journal of Cancer.
[14] A. Sytkowski,et al. Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction , 2014, Front. Immunol..
[15] R. Motzer,et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[17] R. Motzer,et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[18] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[19] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[20] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[21] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[22] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.